Patent · US Active

Anti-C5a binding moieties with high blocking activity

US9458233B2 · kind B2 · utility

11Cited by

2References

28Claims

0Family size

Assignee

InflaRx GmbH · DE

Inventors

Renfeng Guo · Ann Arbor, US
Niels Christoph Riedemann · Jena, DE
Yan Li · Tallahassee, US
Beifen Shen · Beijing, CN

Key dates

Filing date	Jun 3, 2015
Grant date	Oct 4, 2016
Priority date	—
Expiry date	Jun 3, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.